Tracking the Evolution of MultipleIn VitroHepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep Sequencing
- 1 November 2010
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 84 (21) , 11124-11133
Abstract
Resistance to hepatitis C virus (HCV) inhibitors targeting viral enzymes has been observed inin vitroreplicon studies and during clinical trials. The factors determining the emergence of resistance and the changes in the viral quasispecies population under selective pressure are not fully understood. To assess the dynamics of variants emergingin vitrounder various selective pressures with TMC380765, a potent macrocyclic HCV NS3/4A protease inhibitor, HCV genotype 1b replicon-containing cells were cultured in the presence of a low, high, or stepwise-increasing TMC380765 concentration(s). HCV replicon RNA from representative samples thus obtained was analyzed using (i) population, (ii) clonal, and (iii) 454 deep sequencing technologies. Depending on the concentration of TMC380765, distinct mutational patterns emerged. In particular, culturing with low concentrations resulted in the selection of low-level resistance mutations (F43S and A156G), whereas high concentrations resulted in the selection of high-level resistance mutations (A156V, D168V, and D168A). Clonal and 454 deep sequencing analysis of the replicon RNA allowed the identification of low-frequency preexisting mutations possibly contributing to the mutational pattern that emerged. Stepwise-increasing TMC380765 concentrations resulted in the emergence and disappearance of multiple replicon variants in response to the changing selection pressure. Moreover, two different codons for the wild-type amino acids were observed at certain NS3 positions within one population of replicons, which may contribute to the emerging mutational patterns. Deep sequencing technologies enabled the study of minority variants present in the HCV quasispecies population present at baseline and during antiviral drug pressure, giving new insights into the dynamics of resistance acquisition by HCV.Keywords
This publication has 56 references indexed in Scilit:
- Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C VirusScience Translational Medicine, 2010
- Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencingAIDS, 2009
- GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796Antimicrobial Agents and Chemotherapy, 2009
- Ultra‐Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse‐Transcriptase Inhibitor (NRTI)–Treated Patients and NRTI‐Naive PatientsThe Journal of Infectious Diseases, 2009
- The 30th anniversary of quasispeciesEMBO Reports, 2009
- Temporal Dynamics of a Predominant Protease Inhibitor–Resistance Mutation in a Treatment-Naive, Hepatitis C Virus–Infected IndividualThe Journal of Infectious Diseases, 2009
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsHepatology, 2008
- Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?Journal of Antimicrobial Chemotherapy, 2008
- Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon SystemAntimicrobial Agents and Chemotherapy, 2008
- Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistanceGenome Research, 2007